☆ 4.7 Editorial Material

p53 Function and Dysfunction in Human Health and Diseases

BIOMOLECULES (2023)

Related references

Note: Only part of the references are listed.

Review Biochemistry & Molecular Biology

NRF2 in Cancer: Cross-Talk with Oncogenic Pathways and Involvement in Gammaherpesvirus-Driven Carcinogenesis

Mara Cirone et al.

Summary: Expanding the understanding of the molecular mechanisms in tumor development, especially the interaction between oncogenic pathways, may lead to improved personalized cancer therapies. Nuclear factor erythroid 2-related factor 2 (NRF2) is crucial in cancer progression, not only due to its antioxidant activity but also its cross-talk with several oncogenic pathways. Additionally, NRF2's involvement in gammaherpesvirus-driven carcinogenesis is intriguing, as these viruses utilize the NRF2 pathway to protect tumor cells and avoid excessive reactive oxygen species levels. Manipulating the NRF2 pathway at different stages of gammaherpesvirus-mediated carcinogenesis may have varying outcomes, making it a potential target for cancer therapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Biochemistry & Molecular Biology

The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer

Bryce Wallis et al.

Summary: It is well known that p53 mutations are common in cancer tumors, including ovarian cancer. Ovarian cancer is often diagnosed at later stages and has a low survival rate, especially for high-grade serous ovarian carcinoma (HGSOC) which has a high prevalence of p53 mutations. Previous p53-based therapies for ovarian cancer have faced challenges and limited success. This review discusses the failures of historical p53-targeted therapeutics and the potential for new generation therapies.

BIOMOLECULES (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Tumor Suppressor Role of Wild-Type P53-Dependent Secretome and Its Proteomic Identification in PDAC

Giovanna Butera et al.

Summary: The study of the cancer secretome is essential for understanding the role of wild-type p53 in the cancer microenvironment. This research demonstrates the tumor suppressive effects of wild-type p53 on cancer cell secretome in pancreatic ductal adenocarcinoma (PDAC). By using high-resolution SWATH-MS technology, the researchers identified several secreted proteins that are involved in cancer-related processes, with their secretion levels altered in response to p53 silencing.

BIOMOLECULES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

MDM2-Driven Ubiquitination Rapidly Removes p53 from Its Cognate Promoters

Kester Mo Henningsen et al.

Summary: MDM2 can remove p53 from promoters by rapidly terminating its interactions with chromatin in a ubiquitin-dependent manner, in addition to its antagonism through covering the transactivation domain and destabilization.

BIOMOLECULES (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Cross-Talk between p53 and Wnt Signaling in Cancer

Qiyun Xiao et al.

Summary: Targeting cancer hallmarks is crucial for improving anti-cancer treatment, but cross-talk between signaling pathways often leads to resistance. This article provides an overview of the molecular interactions between the p53 and Wnt pathways in cancer, including complex feedback loops and reciprocal transactivation, as well as the mutational landscape of genes associated with these pathways.

BIOMOLECULES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

TP53 Pathogenic Variants in Early-Onset Breast Cancer Patients Fulfilling Hereditary Breast and Ovary Cancer and Li-Fraumeni-like Syndromes

Paula Francinete Faustino da Silva et al.

Summary: TP53 gene mutations are associated with breast cancer. A study of 83 breast cancer patients in the Midwest region of Brazil found that 4 patients had pathogenic variants in the TP53 gene, highlighting the importance of genetic testing in this group.

BIOMOLECULES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

The Impact of NRF2 Inhibition on Drug-Induced Colon Cancer Cell Death and p53 Activity: A Pilot Study

Alessia Garufi et al.

Summary: This study investigates the role of NRF2 in cell response to chemotherapeutic drugs in colon cancer cells. The results show that NRF2 activation can protect cells from drug-induced DNA damage and apoptosis, reducing cell death. Furthermore, inhibiting NRF2 pathway can restore p53 activity and enhance the cytotoxic effects of chemotherapy drugs. These findings provide experimental evidence for the inhibition of NRF2 and combination therapies.

BIOMOLECULES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Early Social Enrichment Modulates Tumor Progression and p53 Expression in Adult Mice

Silvia Middei et al.

Summary: Epidemiological evidence suggests that stress and aversive psychological conditions can influence cancer progression, while well-being can provide protection. This study used mice to demonstrate that being raised in a positive psychological environment can confer protection against tumor development. The involvement of p53 and p21 proteins may play a role in this protective effect.

BIOMOLECULES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

p53-R273H Sustains ROS, Pro-Inflammatory Cytokine Release and mTOR Activation While Reducing Autophagy, Mitophagy and UCP2 Expression, Effects Prevented by wtp53

Maria Anele Romeo et al.

Summary: Mutations in the p53 gene, such as p53-R273H, can promote cancer cell survival by increasing intracellular ROS level, releasing pro-inflammatory/immune suppressive cytokines, activating mTOR, reducing autophagy and mitophagy, and downregulating UCP2. Wild type p53 may counteract the pro-tumorigenic activities of p53-R273H, resulting in lower aggressiveness in cancers carrying heterozygous mutp53 compared to those with homozygous mutp53.

BIOMOLECULES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

p53-Mediated Radiosensitization of 177Lu-DOTATATE in Neuroblastoma Tumor Spheroids

Sara Lundsten et al.

Summary: The study investigated the novel p53-stabilizing peptide VIP116 in neuroblastoma, both as monotherapy and in combination with Lu-177-DOTATATE. Results showed that VIP116 inhibited neuroblastoma cell growth, potentiated Lu-177-DOTATATE treatment, and demonstrated synergistic effects in combination therapy, making it a feasible treatment option for neuroblastoma.

BIOMOLECULES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Inhibition of CNOT2 Induces Apoptosis via MID1IP1 in Colorectal Cancer Cells by Activating p53

Ji Hoon Jung et al.

Summary: The study found that CNOT2 induces apoptosis in colorectal cancer cells by activating p53 and prolonging its half-life. CNOT2 also collaborates with MID1IP1 to promote c-Myc expression.

BIOMOLECULES (2021)

Add to Collection

Review Oncology

Mutant p53 and Cellular Stress Pathways: A Criminal Alliance That Promotes Cancer Progression

Gabriella D'Orazi et al.

CANCERS (2019)

Add to Collection

Review Oncology

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Kanaga Sabapathy et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection

Review Oncology

Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target

Ramona Schulz-Heddergott et al.

CANCERS (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Putting p53 in Context

Edward R. Kastenhuber et al.

CELL (2017)

Add to Collection

Article Oncology

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Patricia A. J. Muller et al.

CANCER CELL (2014)

Add to Collection

Article Cell Biology

Degradation of mutant p53H175 protein by Zn(II) through autophagy

A. Garufi et al.

CELL DEATH & DISEASE (2014)

Add to Collection

Article Cell Biology

Chaperone-mediated autophagy degrades mutant p53

Helin Vakifahmetoglu-Norberg et al.

GENES & DEVELOPMENT (2013)

Add to Collection

Article Oncology

Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells

Mara Cirone et al.

ONCOIMMUNOLOGY (2013)

Add to Collection

Article Oncology

Allele-Specific p53 Mutant Reactivation

Xin Yu et al.

CANCER CELL (2012)

Add to Collection

Article Cell Biology

Dietary downregulation of mutant p53 levels via glucose restriction Mechanisms and implications for tumor therapy

Olga Catalina Rodriguez et al.

CELL CYCLE (2012)

Add to Collection

Article Cell Biology

Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs

Rosa Puca et al.

CELL CYCLE (2011)

Add to Collection

Article Multidisciplinary Sciences

p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis

L Sivaraman et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.